Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kazuo Tubaki"'
Autor:
Yasuaki Shida, Yoshihiro Fujimura, Hideo Yagi, Naoko Yamaguchi, Kazuo Tubaki, Masanori Matsumoto, Mitsuhiko Sugimoto
Publikováno v:
Thrombosis Research. 159:91-95
Upshaw-Schulman syndrome (USS) is a thrombo-hemorrhagic disease caused by congenital deficiency of ADAMTS13 due to ADAMTS13 gene mutations. USS is characterized by repeated episodes of thrombocytopenia and microangiopathic hemolytic anemia that respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf534d9694b47b0cdc21b19ce5c26d90
https://doi.org/10.1016/j.thromres.2017.10.007
https://doi.org/10.1016/j.thromres.2017.10.007
Autor:
Yasuhiro Ohba, Ikunosuke Sakurabayashi, Atushi Horiuchi, Kazuo Tubaki, Yasurou Obana, Tosiyuki Akiyama, Kazuhiko Yamamoto, Mayumi Imoto, Hyogo Sinohara, Itaru Furuta
Publikováno v:
SEIBUTSU BUTSURI KAGAKU. 39:5-12
今回われわれは, 凝固異常を伴う過粘稠度症候群の1例において, 37℃以下の低温で患者血漿をゲル化させるIgA1-λ型M蛋白をみいだし, その免疫化学的特性について検討した. その結果, 患者
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2b91718af5139423b5cce69430d945f
https://doi.org/10.2198/sbk.39.5
https://doi.org/10.2198/sbk.39.5
Autor:
Ken Hamada, Tatsuo Yudate, Tadashi Tezuka, Hikikazu Yamada, Junichi Chihara, Keiji Maeda, Masaharu Matsukura, Kazuo Tubaki
Publikováno v:
The Journal of allergy and clinical immunology. 100(6 Pt 2)
Background: Early diagnosis of graft-versus-host-disease (GVHD) after bone marrow transplantation is often difficult, particularly when the patients are immunosuppressed by chemotherapy or irradiation. Objective: To investigate the influence of cytok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51f6cf2a52a3553e7fbaa32b4ac268f4
https://pubmed.ncbi.nlm.nih.gov/9440549
https://pubmed.ncbi.nlm.nih.gov/9440549
Autor:
Fujita Mariko, Ryosuke Fujiwara, Hitoshi Hanamoto, Kazuo Tubaki, Keiko Yamazaki, Hideo Yagi, Takashi Iizuka, Keigo Sano
Publikováno v:
Blood. 120:1865-1865
Abstract 1865 Background: The three drugs combination of cyclophosphamide, bortezomib and dexamethasone (CyBorD) has been proven to be a powerful regimen for the treatment of the patients with multiple myeloma (MM). However, twice-weekly schedule of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f118bd4df318aead60637b079b971a8a
https://doi.org/10.1182/blood.v120.21.1865.1865
https://doi.org/10.1182/blood.v120.21.1865.1865